journal
https://read.qxmd.com/read/38493411/modelling-the-public-health-burden-of-herpes-zoster-and-the-impact-of-adjuvanted-recombinant-zoster-vaccine-in-five-selected-countries-in-southeast-asia
#21
JOURNAL ARTICLE
Ru Han, Peter San Martin, Nurilign Ahmed, Adriana Guzman-Holst, Ahmed Mohy, Thatiana Pinto, Bruna de Veras, Jorge A Gomez, Gyneth Lourdes Bibera, Désirée A M van Oorschot
INTRODUCTION: Herpes zoster (HZ) can cause substantial patient morbidity and lead to large healthcare costs. However, the disease burden of HZ in Southeast Asia may be underestimated. This study aimed to estimate the public health burden of HZ and the impact of vaccinating adults aged ≥ 50 years old in five Southeast Asian countries (Indonesia, Malaysia, Philippines, Thailand, and Vietnam), with adjuvanted recombinant zoster vaccine (RZV) compared with no vaccination...
March 17, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38491269/cost-effectiveness-of-20-valent-pneumococcal-conjugate-vaccine-among-us-children-with-underlying-medical-conditions
#22
JOURNAL ARTICLE
Mark H Rozenbaum, Erica Chilson, Raymond Farkouh, Liping Huang, Alejandro Cane, Adriano Arguedas, Maria J Tort, Vincenza Snow, Ahuva Averin, Derek Weycker, Dhwani Hariharan, Mark Atwood
INTRODUCTION: A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions (CMC+) and children aged 6 years with immunocompromising conditions (IC) versus one and two doses of 23-valent pneumococcal polysaccharide vaccine (PPSV23), respectively. METHODS: A probabilistic model was employed to depict 10-year risk of clinical outcomes and economic costs of pneumococcal disease, reduction in life years from premature death, and expected impact of vaccination among one cohort of children with CMC+ and IC aged 6 years...
March 16, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38489119/distinct-lipidomic-profiles-between-people-living-with-hiv-treated-with-e-c-f-taf-or-b-f-taf-an-open-label-prospective-cohort-study
#23
JOURNAL ARTICLE
Zhikai Wan, Junwei Su, Xueling Zhu, Xiang Liu, Yongzheng Guo, Dairong Xiang, Xiaotang Zhou, Xiaorong Peng, Ran Tao, Qing Cao, Guanjing Lang, Ying Huang, Biao Zhu
INTRODUCTION: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) has been increasingly replaced by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in the treatment of human immunodeficiency virus (HIV) owing to its more favorable pharmacokinetics and fewer drug-drug interactions. However, the effect of this switch on plasma lipids and lipidomic profiles remains poorly characterized. METHODS: HIV infected patients on an E/C/F/TAF regimen were recruited into the study and followed up every 12 weeks...
March 15, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38489118/k-means-clustering-identifies-diverse-clinical-phenotypes-in-covid-19-patients-implications-for-mortality-risks-and-remdesivir-impact
#24
JOURNAL ARTICLE
Carolina Garcia-Vidal, Christian Teijón-Lumbreras, Tommaso Francesco Aiello, Mariana Chumbita, Rosario Menendez, Aina Mateu-Subirà, Olivier Peyrony, Patricia Monzó, Carlos Lopera, Antonio Gallardo-Pizarro, Raúl Méndez, Esther Calbo, Mariona Xercavins, Genoveva Cuesta-Chasco, José A Martínez, Ma Angeles Marcos, Josep Mensa, Alex Soriano
INTRODUCTION: The impact of remdesivir on mortality in patients with COVID-19 is still controversial. We aimed to identify clinical phenotype clusters of COVID-19 hospitalized patients with highest benefit from remdesivir use and validate these findings in an external cohort. METHODS: We included consecutive patients hospitalized between February 2020 and February 2021 for COVID-19. The derivation cohort comprised subjects admitted to Hospital Clinic of Barcelona...
March 15, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38489117/serum-troponin-i-assessments-in-5-to-30-year-olds-after-bnt162b2-vaccination
#25
JOURNAL ARTICLE
Timothy E Albertson, Caitlin Hansen, Smiti Bihari, Juleen Gayed, Xia Xu, J Abraham Simón-Campos, Michael E Dever, Jose F Cardona, Essack Mitha, Jeffrey B Baker, Georgina Keep, Islamiat Oladipupo, Federico J Mensa, Ye Feng, Hua Ma, Kenneth Koury, Susan Mather, Claudia Ana Ianos, Annaliesa S Anderson, Özlem Türeci, Uǧur Şahin, William C Gruber, Alejandra Gurtman, Charu Sabharwal, Nicholas Kitchin
INTRODUCTION: Rare myocarditis and pericarditis cases have occurred in coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccine recipients. Troponin levels, a potential marker of myocardial injury, were assessed in healthy participants before and after BNT162b2 vaccination. METHODS: Vaccine-experienced 12- to 30-year-olds in phase 3 crossover C4591031 Substudy B (NCT04955626) who had two or three prior BNT162b2 30-μg doses were randomized to receive BNT162b2 30 μg followed by placebo, or placebo followed by BNT162b2 30 µg, 1 month apart...
March 15, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38485847/podcast-need-for-quality-evidence-for-decision-making-on-seasonal-influenza-vaccines
#26
JOURNAL ARTICLE
Ann R Falsey, Stefania Maggi, Tor Biering-Sørensen
Seasonal influenza is usually considered an acute respiratory infection with a full recovery within a week. In addition to the traditional outcomes, there is now evidence of indirect effects in terms of neurological and functional complications. Major organ systems can be affected, underlining the need for preventative measures against infection. The aim of this podcast, featuring Dr. Ann Falsey, Dr. Stefania Maggi, and Dr. Tor Biering-Sørensen, is to outline influenza complications beyond acute respiratory disease, as well as discussing the need for quality of evidence when evaluating influenza vaccines...
March 14, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38483776/effect-of-infusion-set-replacement-intervals-on-central-line-associated-bloodstream-infection-in-the-intensive-care-unit-study-protocol-of-the-inspiration-study
#27
JOURNAL ARTICLE
Dandan Xu, Chang Hu, Jie Xiong, Haiyan Huang, Shasha Wang, Xinbo Ding, Junying Zhou, Juan Deng, Chunling Guo, Miqi Li, Ting You, Wei Cheng, Bo Li, Xiaoqin Tang, Xiaohong Li, Hongmei Li, Jin Li, Jing Ma, Meng Xiao, Xing Fu, Huilin Li, Zhiyong Peng, Bo Hu, Fen Hu
INTRODUCTION: The replacement intervals for infusion sets may differ among healthcare institutions, which may have an impact on the occurrence of central line-associated bloodstream infections (CLABSI). Nevertheless, there exists a limited amount of high-quality evidence available to assist clinicians in determining the most suitable replacement intervals for infusion sets. Therefore, the objective of this trial is to compare the efficacy of 24-h and 96-h replacement intervals for infusion sets on CLABSI among critically ill adults who have central venous access devices...
March 14, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38483775/household-influenza-transmission-and-healthcare-resource-utilization-among-patients-treated-with-baloxavir-vs-oseltamivir-a-united-states-outpatient-prospective-survey
#28
JOURNAL ARTICLE
Jennie H Best, Mitra Sadeghi, Xiaowu Sun, Arpamas Seetasith, Lisa Albensi, Seema Joshi, Marcus J Zervos
INTRODUCTION: Influenza is a common, seasonal infectious disease with broad medical, economic, and social consequences. Real-world evidence on the effect of influenza treatment on household transmission and healthcare resource utilization is limited in outpatient settings in the USA. This study examined the real-world effectiveness of baloxavir vs oseltamivir in reducing influenza household transmission and healthcare resource utilization. METHODS: This prospective electronic survey on patient-reported outcomes was conducted between October 2022 and May 2023 via CVS Pharmacy in the USA...
March 14, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38461481/epidemiology-of-reportable-bacterial-infectious-diseases-in-saudi-arabia
#29
JOURNAL ARTICLE
Nada K Alhumaid, Areej M Alajmi, Nada F Alosaimi, Maryam Alotaibi, Thamer A Almangour, Majed S Nassar, Ziad A Memish, Abdulwahab Z Binjomah, Ahmed Al-Jedai, Abdulaziz S Almutairi, Saeed Algarni, Noura M Alshiban, Munirah S Aleyiydi, Abdulkader F Tawfik, Atef Shibl, Essam A Tawfik
INTRODUCTION: Bacterial infections have a significant impact on human health; they can cause severe morbidity and mortality, particularly in susceptible populations. Epidemiological surveillance is a critical tool for monitoring the population's health and facilitate the prevention and control of infectious disease outbreaks. Knowing the burden of bacterial communicable diseases is an initial core step toward public health goals. METHODS: Saudi epidemiology surveillance data were utilized to depict the changing epidemiology of bacterial infectious diseases in Saudi Arabia from 2018 to 2021...
March 10, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38461480/longitudinal-molecular-and-serological-evidence-of-sars-cov-2-infections-and-vaccination-status-community-based-surveillance-study-contact
#30
JOURNAL ARTICLE
Olga Sánchez-Soliño, Ryan D Kilpatrick, Christopher Johnson, Yixin Fang, Yizhou Ye, Negar Niki Alami, Katarzyna Zarish, Whitney S Krueger, Nancy Dreyer, Gregory C Gray
INTRODUCTION: This prospective, longitudinal, community-based study, EpidemiologiCal POpulatioN STudy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Lake CounTy, Illinois (CONTACT), investigated coronavirus disease 2019 (COVID-19) immunity, occupational risks related to SARS-CoV-2 exposure, and long-term immunoglobulin G (IgG) seroconversion kinetics. METHODS: At baseline and follow up (3, 6, and 9 months), non-hospitalized adult participants provided nasal and blood serum specimens for molecular [reverse transcription polymerase chain reaction (RT-PCR)] and serological (IgG) testing (4 November 2020-30 October 2021)...
March 10, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38460083/clinical-characteristics-of-uncomplicated-acute-pyelonephritis-caused-by-escherichia-coli-and-klebsiella-pneumoniae
#31
JOURNAL ARTICLE
Miri Hyun, Ji Yeon Lee, Kyong Ree Lim, Hyun Ah Kim
INTRODUCTION: This study compared the clinical characteristics and antimicrobial susceptibility of uncomplicated acute pyelonephritis (APN) caused by Escherichia coli and Klebsiella pneumoniae. METHODS: We retrospectively reviewed the medical records of patients with uncomplicated APNs caused by E. coli and K. pneumoniae admitted to Keimyung University Dongsan Hospital between February 2014 and December 2021. RESULTS: We enrolled 497 patients (372 with E...
March 9, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38460082/effect-of-renal-impairment-on-pharmacokinetics-and-safety-of-ensitrelvir-a-sars-cov-2-3cl-protease-inhibitor
#32
JOURNAL ARTICLE
Takayuki Katsube, Safwan Kezbor, Ryosuke Shimizu, Ryuji Kubota
INTRODUCTION: Ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, shows efficacy and safety in participants with mild to moderate COVID-19. Since urinary recovery of ensitrelvir ranged from 12.9% to 21.8% across dose groups given 20-1000 mg in a single-ascending dose study, renal excretion contributes to the elimination of ensitrelvir. Therefore, the effect of renal impairment on the pharmacokinetics and safety of ensitrelvir needed to be evaluated. METHODS: This study (NCT05363215) was a phase 1, open-label, nonrandomized, parallel-group study...
March 9, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38459236/amoebic-liver-abscess-potential-application-of-new-diagnostic-techniques-for-an-old-pathogen
#33
JOURNAL ARTICLE
Federica Portunato, Claudia Bartalucci, Antonio Vena, Daniele Roberto Giacobbe, Elisa Porcile, Paolo Montanelli, Nataniele Piol, Monica Centanaro, Enzo Andorno, Matteo Bassetti
Amoebic liver abscess is a severe and potentially life-threatening infection requiring prompt diagnosis and early targeted treatment. Diagnosis is challenging because conventional diagnostic methods such as light microscopy and serology are often unreliable. Molecular techniques have emerged as an additional diagnostic tool, suddenly becoming the new diagnostic reference standard. More recently, commercial multiplex PCR panels, including FilmArray, have been introduced, which permit the simultaneous detection of several enteric pathogens including Entamoeba histolytica in stool samples...
March 8, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38457110/living-during-covid-19-while-immunocompromised-a-patient-and-physician-perspective-from-france
#34
JOURNAL ARTICLE
Elise Foudrat, Sophie Caillard
This article is co-authored by a kidney transplant recipient and her nephrologist. By sharing her personal experience of the coronavirus disease 2019 (COVID-19) pandemic, the patient illustrates the concerns of immunocompromised patients during this unprecedented health crisis. She describes the difficulties encountered at work, the omnipresent protective measures, and the need for appropriate information. The nephrologist, who follows a cohort of over 1700 kidney transplant recipients, recounts the medical team's struggle to protect their vulnerable patients against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as a veritable succession of hopes and disappointments...
March 8, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38441844/the-impact-of-the-covid-19-pandemic-on-the-incidence-of-herpes-zoster-a-narrative-literature-review
#35
REVIEW
Raunak Parikh, Mitra Yousefi, Desmond Curran, Robyn Widenmaier
Coronavirus disease 2019 (COVID-19) has had a broad impact on health services and health outcomes. During the pandemic, there were numerous reports of herpes zoster (HZ) in people with COVID-19 and in COVID-19 vaccine recipients. The aim of this review is to elucidate the global effects of the COVID-19 pandemic on HZ. It is postulated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces an immunosuppressive state that favours varicella zoster virus (VZV) reactivation. Three large cohort studies (a multinational study and studies from the USA and Spain) that excluded individuals vaccinated against HZ reported significantly increased risk of HZ following COVID-19 infection, especially in people aged ≥ 50 years...
March 5, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38430327/4cmenb-vaccination-to-prevent-meningococcal-b-disease-in-vietnam-expert-review-and-opinion
#36
JOURNAL ARTICLE
Phung Nguyen The Nguyen, Pham Quang Thai, Tran Minh Dien, Do Thien Hai, Vo Thi Trang Dai, Nguyen Huy Luan, Gaurav Mathur, Selim Badur, Doan Minh Truyen, Nguyen Hoan Le Minh
An advisory board meeting was held with experts in Vietnam (Hanoi, August 2022), to review the evidence on invasive meningococcal disease (IMD) epidemiology, clinical management, and meningococcal vaccines to reach a consensus on recommendations for meningococcal vaccination in Vietnam. IMD is a severe disease, with the highest burden in infants and children. IMD presents as meningitis and/or meningococcemia and can progress extremely rapidly. Almost 90% of deaths in children occur within the first 24 h, and disabling sequelae (e...
March 2, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38427290/direct-acting-antivirals-remain-cost-effective-treatments-for-chronic-hepatitis-c-in-australia-despite-changes-to-the-treated-population-and-the-availability-of-retreatment-the-glecaprevir-pibrentasvir-maviret-%C3%A2-example
#37
JOURNAL ARTICLE
Emma Warren, Belinda J C Castles, Gillian C Sharratt, Aitor Arteaga
INTRODUCTION: The first direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection were reimbursed via Australia's Pharmaceutical Benefits Scheme (PBS) in March 2016. This was based on the recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) that the regimens would be acceptably cost-effective at an incremental cost-effectiveness ratio (ICER) no greater than $15,000/quality-adjusted life-year (QALY). Since the initial PBS listings for DAA therapies and subsequent listings of newer DAA treatments such as glecaprevir/pibrentasvir (Maviret® ), the demographics and some of the disease characteristics of currently treated patients have markedly changed...
March 1, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38427289/dalbavancin-sequential-therapy-for-gram-positive-bloodstream-infection-a-multicenter-observational-study
#38
JOURNAL ARTICLE
Nicholas Rebold, Sara Alosaimy, Jeffrey C Pearson, Brandon Dionne, Ahmad Taqi, Abdalhamid Lagnf, Kristen Lucas, Mark Biagi, Nicholas Lombardo, Joshua Eudy, Daniel T Anderson, Monica V Mahoney, Wesley D Kufel, Joseph A D'Antonio, Bruce M Jones, Jeremy J Frens, Tyler Baumeister, Matthew Geriak, George Sakoulas, Dimitrios Farmakiotis, Dino Delaportas, Jeremy Larew, Michael P Veve, Michael J Rybak
INTRODUCTION: Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI), particularly in those with barriers to discharge or who require prolonged parenteral antibiotic courses. A retrospective cohort study was performed to provide further multicenter real-world evidence on dalbavancin use as a sequential therapy for Gram-positive BSI. METHODS: One hundred fifteen patients received dalbavancin with Gram-positive BSI, defined as any positive blood culture or diagnosed with infective endocarditis, from 13 centers geographically spread across the United States between July 2015 and July 2021...
March 1, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38421519/oritavancin-versus-daptomycin-for-osteomyelitis-treatment-after-surgical-debridement
#39
JOURNAL ARTICLE
Nicholas W Van Hise, Russell M Petrak, Kairav Shah, Melina Diaz, Vishnu Chundi, Mark Redell
INTRODUCTION: Weekly intravenous (IV) oritavancin and daily daptomycin were compared in an outpatient setting following extensive surgical debridement for treating patients with osteomyelitis. METHODS: This was a retrospective, observational study of patients diagnosed with acute osteomyelitis. Exclusion criteria were the use of Gram-negative antibiotic therapy, use of antibiotics for more than 48 h prior to oritavancin or daptomycin or prior use of > 2 doses of oritavancin or more than 4 weeks of daptomycin...
February 29, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38403865/safety-efficacy-and-pharmacokinetics-of-azd7442-tixagevimab-cilgavimab-for-treatment-of-mild-to-moderate-covid-19-15-month-final-analysis-of-the-tackle-trial
#40
JOURNAL ARTICLE
F D Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón-Campos, Douglas Arbetter, Seth Seegobin, Alexandre Kiazand, Katie Streicher, Nuria Martinez-Alier, Taylor S Cohen, Mark T Esser
INTRODUCTION: In the phase 3 TACKLE study, outpatient treatment with AZD7442 (tixagevimab/cilgavimab) was well tolerated and significantly reduced progression to severe disease or death through day 29 in adults with mild-to-moderate coronavirus disease 2019 (COVID-19) at the primary analysis. Here, we report data from the final analysis of the TACKLE study, performed after approximately 15 months' follow-up. METHODS: Eligible participants were randomized 1:1 and dosed within 7 days of symptom onset with 600 mg intramuscular AZD7442 (n = 456; 300 mg tixagevimab/300 mg cilgavimab) or placebo (n = 454)...
February 25, 2024: Infectious Diseases and Therapy
journal
journal
48936
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.